These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 29507618

  • 1. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.
    Wu DW, Wang YC, Wang L, Chen CY, Lee H.
    Theranostics; 2018; 8(5):1256-1269. PubMed ID: 29507618
    [Abstract] [Full Text] [Related]

  • 2. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS, Park DI, Lee DH, Lee JE, Yeo MK, Park YH, Lim DS, Choi W, Lee DH, Yoo G, Kim HB, Kang D, Moon JY, Jung SS, Kim JO, Cho SY, Park HS, Chung C.
    Biochem Biophys Res Commun; 2017 Sep 16; 491(2):493-499. PubMed ID: 28684311
    [Abstract] [Full Text] [Related]

  • 3. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    Kang DH, Jung SS, Yeo MK, Lee DH, Yoo G, Cho SY, Oh IJ, Kim JO, Park HS, Chung C, Lee JE.
    BMC Cancer; 2020 Jun 18; 20(1):571. PubMed ID: 32552717
    [Abstract] [Full Text] [Related]

  • 4. Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival.
    Hong SA, Jang SH, Oh MH, Kim SJ, Kang JH, Hong SH.
    Pathol Res Pract; 2018 Mar 18; 214(3):335-342. PubMed ID: 29487002
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.
    Wang YC, Wu DW, Wu TC, Wang L, Chen CY, Lee H.
    Int J Biol Sci; 2018 Mar 18; 14(1):47-56. PubMed ID: 29483824
    [Abstract] [Full Text] [Related]

  • 7. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.
    Wu DW, Wu TC, Chen CY, Lee H.
    Clin Cancer Res; 2016 Nov 01; 22(21):5370-5382. PubMed ID: 27178741
    [Abstract] [Full Text] [Related]

  • 8. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL, Wu TC, Wu DW, Wang L, Chen CY, Lee H.
    Eur J Cancer; 2017 Nov 01; 85():95-105. PubMed ID: 28892778
    [Abstract] [Full Text] [Related]

  • 9. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
    Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, Vivanco GL, Vergnenegre A, Sanchez JM, Provencio M, de Marinis F, Passaro A, Carcereny E, Reguart N, Campelo CG, Teixido C, Sperduti I, Rodriguez S, Lazzari C, Verlicchi A, de Aguirre I, Queralt C, Wei J, Estrada R, Puig de la Bellacasa R, Ramirez JL, Jacobson K, Ditzel HJ, Santarpia M, Viteri S, Molina MA, Zhou C, Cao P, Ma PC, Bivona TG, Rosell R.
    J Natl Cancer Inst; 2017 Sep 01; 109(9):. PubMed ID: 28376152
    [Abstract] [Full Text] [Related]

  • 10. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY, Liu YN, Wu SG, Hsu CL, Chang TH, Tsai MF, Lin YT, Shih JY.
    Cancer Biomark; 2020 Sep 01; 28(3):351-363. PubMed ID: 32417760
    [Abstract] [Full Text] [Related]

  • 11. MicroRNA‑506‑3p reverses gefitinib resistance in non‑small cell lung cancer by targeting Yes‑associated protein 1.
    Zhu J, Tao L, Jin L.
    Mol Med Rep; 2019 Feb 01; 19(2):1331-1339. PubMed ID: 30535506
    [Abstract] [Full Text] [Related]

  • 12. miR-608 and miR-4513 significantly contribute to the prognosis of lung adenocarcinoma treated with EGFR-TKIs.
    Zhang N, Li Y, Zheng Y, Zhang L, Pan Y, Yu J, Yang M.
    Lab Invest; 2019 Apr 01; 99(4):568-576. PubMed ID: 30552364
    [Abstract] [Full Text] [Related]

  • 13. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J, Lv D, Wang C, Li L, Zhao Q, Chen H, Xu L.
    Oncogene; 2018 Aug 01; 37(31):4300-4312. PubMed ID: 29717264
    [Abstract] [Full Text] [Related]

  • 14. Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.
    Kinehara Y, Nagatomo I, Koyama S, Ito D, Nojima S, Kurebayashi R, Nakanishi Y, Suga Y, Nishijima-Futami Y, Osa A, Nakatani T, Kato Y, Nishide M, Hayama Y, Higashiguchi M, Morimura O, Miyake K, Kang S, Minami T, Hirata H, Iwahori K, Takimoto T, Takamatsu H, Takeda Y, Hosen N, Hoshino S, Shintani Y, Okumura M, Kumagai T, Nishino K, Imamura F, Nakatsuka SI, Kijima T, Kida H, Kumanogoh A.
    JCI Insight; 2018 Dec 20; 3(24):. PubMed ID: 30568033
    [Abstract] [Full Text] [Related]

  • 15. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B, Ren S, Li X, Wang Y, Garfield D, Zhou S, Chen X, Su C, Chen M, Kuang P, Gao G, He Y, Fan L, Fei K, Zhou C, Schmit-Bindert G.
    Lung Cancer; 2014 Feb 20; 83(2):146-53. PubMed ID: 24331411
    [Abstract] [Full Text] [Related]

  • 16. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    Ge P, Cao L, Chen X, Jing R, Yue W.
    BMC Cancer; 2019 Dec 10; 19(1):1203. PubMed ID: 31823748
    [Abstract] [Full Text] [Related]

  • 17. Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability.
    Wu DW, Chen CY, Chu CL, Lee H.
    Oncogene; 2016 Feb 04; 35(5):621-30. PubMed ID: 25915848
    [Abstract] [Full Text] [Related]

  • 18. HDAC1 and FOXK1 mediate EGFR-TKI resistance of non-small cell lung cancer through miR-33a silencing.
    Liu J, Wang W, Wang K, Liu W, Zhao Y, Han X, Wang L, Jiang BH.
    J Transl Med; 2024 Aug 28; 22(1):793. PubMed ID: 39198847
    [Abstract] [Full Text] [Related]

  • 19. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T, Ishii G, Goto K, Neri S, Hashimoto H, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Iida S, Niimi A, Nagai K, Ohe Y, Ochiai A.
    Clin Cancer Res; 2015 Feb 01; 21(3):642-51. PubMed ID: 25388165
    [Abstract] [Full Text] [Related]

  • 20. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
    Kawana S, Saito R, Miki Y, Kimura Y, Abe J, Sato I, Endo M, Sugawara S, Sasano H.
    Cancer Med; 2021 Jan 01; 10(2):718-727. PubMed ID: 33305905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.